During the analyzed period, the six companies part of its portfolio, DocProcess, Medima Health, Clinicile Dentare Dr. Leahu, EMI, Cronos and Stay Fit Gym, posted 106% higher EBITDA from 2021.
Andrei Gemeneanu, Managing Partner of Morphosis Capital, believes that while 2023 will be a challenging year, the fund will stay focused on development and investments in a bid to maintain the 2022 growth pace.
For 2023, the fund holds capital for another investment in a local company or for the potential use of a follow-up capital together with co-investors in one of the six companies already part of its portfolio.
(English version by Catalina Apostoiu)